Inquiry

Classical Hodgkin's Lymphoma (CHL)

Classical Hodgkin's lymphoma (CHL) is a rare form of cancer that primarily affects the lymphatic system, which is an integral part of the body's immune system. Our company remains committed to driving innovation and providing cutting-edge drug and therapy development services for CHL and other rare hematological malignancies.

Introduction to Classical Hodgkin's Lymphoma (CHL)

Classical Hodgkin's lymphoma (CHL) accounts for 95% of HL and has an annual incidence of approximately 1 in 4000 in developed countries, with onset most commonly occurring in young adults aged 15 to 30 years. CHL typically manifests as painless enlargement of lymph nodes, most commonly in the neck, armpits, or groin. It can also affect other organs, such as the spleen, liver, or bone marrow. The disease is diagnosed through a combination of examination, imaging studies, and biopsy.

Pathogenesis of Classical Hodgkin's Lymphoma (CHL)

The pathogenesis of classical Hodgkin's lymphoma involves a complex interplay between the malignant Reed-Sternberg cells and the surrounding immune cells and microenvironment. Several key signaling pathways and genetic alterations have been identified, shedding light on the mechanisms underlying CHL development and progression.

• One of the pivotal events in cHL pathogenesis is the loss of B-cell identity and the acquisition of a unique gene expression program by the Reed-Sternberg cells. This includes the activation of various signaling pathways, such as nuclear factor-kappa B (NF-κB), Janus kinase-signal transducer and activator of transcription (JAK-STAT), and phosphatidylinositol 3-kinase (PI3K) pathways, which promote cell survival, proliferation, and evasion of immune surveillance.
• Additionally, genetic alterations, such as amplification of the 9p24.1 locus, result in overexpression of the PD-L1 and PD-L2 immune checkpoint ligands, leading to immune evasion by the tumor cells. Dysregulation of other genes, including TP53, CD30, and c-REL, further contributes to the pathogenesis of CHL.

Targeted Therapy Development of CHL

• PD-1 Targeted Therapies

Novel therapies have emerged, targeting specific molecular pathways and immune checkpoints. PD-1 inhibitors have shown promising results in the therapy of relapsed or refractory CHL. These immunotherapies work by blocking the interaction between PD-1 on T cells and its ligands, PD-L1 and PD-L2, on tumor cells, thereby reactivating the immune response against CHL.

• CD30 Targeted Therapies

The use of targeted therapies, which specifically target CD30-expressing cells, has demonstrated impressive response rates in relapsed or refractory CHL. These targeted therapies have the advantage of being more precise and minimizing the adverse effects associated with traditional therapies.

• BCR Targeted Therapies

Dysregulation of the B-cell receptor (BCR) signaling pathway has been observed in CHL. Inhibitors targeting key components of this pathway, such as Bruton's tyrosine kinase (BTK) inhibitors, are being investigated as potential therapeutic options for CHL. By blocking the aberrant BCR signaling, these inhibitors aim to disrupt the survival and proliferation of Reed-Sternberg cells.

Our Services

Guided by expert knowledge, our company provides a full range of CHL diagnostics and therapy development services. As your trusted partner in CHL, we are proud to offer custom solutions, carefully crafted to meet any of the biological experts' needs.

Platforms of CHL Therapy Development

The animal model development platform is another major feature of our company, which can help you conduct more in-depth target screening and therapy development for CHL. We also have different animal species for you to choose from for drug safety assessments to intricate pharmacokinetic analyses.

Animal Models of CHL

If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

References

• Cheah, Chan Y., et al. "Marginal zone lymphoma: present status and future perspectives." Haematologica 107.1 (2022): 35.
• Weniger, Marc A., and Ralf Küppers. "Molecular biology of Hodgkin lymphoma." Leukemia 35.4 (2021): 968-981.
• Ansell, Stephen M. "Hodgkin lymphoma: diagnosis and treatment." Mayo Clinic Proceedings. Vol. 90. No. 11. Elsevier, 2015.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.